S&P 500   4,024.86 (+1.35%)
DOW   32,681.47 (+0.89%)
QQQ   313.06 (+1.93%)
AAPL   160.80 (+2.00%)
MSFT   280.63 (+1.96%)
META   205.30 (+2.30%)
GOOGL   101.39 (+0.36%)
AMZN   100.21 (+3.05%)
TSLA   193.23 (+2.14%)
NVDA   270.07 (+2.26%)
NIO   9.85 (+7.07%)
BABA   100.59 (+2.23%)
AMD   96.71 (+2.27%)
T   18.99 (+1.44%)
F   12.05 (+3.88%)
MU   64.29 (+8.45%)
CGC   1.83 (+0.83%)
GE   94.08 (+1.01%)
DIS   96.75 (+2.04%)
AMC   4.98 (-3.30%)
PFE   40.18 (+0.48%)
PYPL   74.24 (+2.12%)
NFLX   331.04 (+2.32%)
S&P 500   4,024.86 (+1.35%)
DOW   32,681.47 (+0.89%)
QQQ   313.06 (+1.93%)
AAPL   160.80 (+2.00%)
MSFT   280.63 (+1.96%)
META   205.30 (+2.30%)
GOOGL   101.39 (+0.36%)
AMZN   100.21 (+3.05%)
TSLA   193.23 (+2.14%)
NVDA   270.07 (+2.26%)
NIO   9.85 (+7.07%)
BABA   100.59 (+2.23%)
AMD   96.71 (+2.27%)
T   18.99 (+1.44%)
F   12.05 (+3.88%)
MU   64.29 (+8.45%)
CGC   1.83 (+0.83%)
GE   94.08 (+1.01%)
DIS   96.75 (+2.04%)
AMC   4.98 (-3.30%)
PFE   40.18 (+0.48%)
PYPL   74.24 (+2.12%)
NFLX   331.04 (+2.32%)
S&P 500   4,024.86 (+1.35%)
DOW   32,681.47 (+0.89%)
QQQ   313.06 (+1.93%)
AAPL   160.80 (+2.00%)
MSFT   280.63 (+1.96%)
META   205.30 (+2.30%)
GOOGL   101.39 (+0.36%)
AMZN   100.21 (+3.05%)
TSLA   193.23 (+2.14%)
NVDA   270.07 (+2.26%)
NIO   9.85 (+7.07%)
BABA   100.59 (+2.23%)
AMD   96.71 (+2.27%)
T   18.99 (+1.44%)
F   12.05 (+3.88%)
MU   64.29 (+8.45%)
CGC   1.83 (+0.83%)
GE   94.08 (+1.01%)
DIS   96.75 (+2.04%)
AMC   4.98 (-3.30%)
PFE   40.18 (+0.48%)
PYPL   74.24 (+2.12%)
NFLX   331.04 (+2.32%)
S&P 500   4,024.86 (+1.35%)
DOW   32,681.47 (+0.89%)
QQQ   313.06 (+1.93%)
AAPL   160.80 (+2.00%)
MSFT   280.63 (+1.96%)
META   205.30 (+2.30%)
GOOGL   101.39 (+0.36%)
AMZN   100.21 (+3.05%)
TSLA   193.23 (+2.14%)
NVDA   270.07 (+2.26%)
NIO   9.85 (+7.07%)
BABA   100.59 (+2.23%)
AMD   96.71 (+2.27%)
T   18.99 (+1.44%)
F   12.05 (+3.88%)
MU   64.29 (+8.45%)
CGC   1.83 (+0.83%)
GE   94.08 (+1.01%)
DIS   96.75 (+2.04%)
AMC   4.98 (-3.30%)
PFE   40.18 (+0.48%)
PYPL   74.24 (+2.12%)
NFLX   331.04 (+2.32%)
NASDAQ:PRTA

Prothena - PRTA Stock Forecast, Price & News

$49.16
+1.04 (+2.16%)
(As of 03/29/2023 03:21 PM ET)
Add
Compare
Today's Range
$48.44
$49.59
50-Day Range
$46.97
$58.27
52-Week Range
$21.06
$66.47
Volume
286,452 shs
Average Volume
495,946 shs
Market Capitalization
$2.58 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$82.50

Prothena MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
67.3% Upside
$82.50 Price Target
Short Interest
Bearish
6.56% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.17mentions of Prothena in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$4.92 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.70) to ($4.60) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.98 out of 5 stars

Medical Sector

628th out of 999 stocks

Pharmaceutical Preparations Industry

308th out of 489 stocks


PRTA stock logo

About Prothena (NASDAQ:PRTA) Stock

Prothena Corp. Plc is a clinical-stage neuroscience company. It focuses on the discovery and development of novel therapies to change the course of devastating diseases. The firm's clinical pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

Receive PRTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prothena and its competitors with MarketBeat's FREE daily newsletter.

PRTA Stock News Headlines

The "King Of Quants" sees 10X potential...
Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...
Prothena (PRTA) Q4 Earnings and Revenues Beat Estimates
The "King Of Quants" sees 10X potential...
Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...
Why Prothena Shares Are Trading Lower
Prothena Third Quarter 2022 Earnings: Misses Expectations
Prothena Corporation PLC
See More Headlines
Receive PRTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prothena and its competitors with MarketBeat's FREE daily newsletter.

PRTA Company Calendar

Last Earnings
2/23/2023
Today
3/29/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PRTA
Employees
82
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$82.50
High Stock Price Forecast
$120.00
Low Stock Price Forecast
$55.00
Forecasted Upside/Downside
+67.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$-116,950,000.00
Net Margins
-216.95%
Pretax Margin
-233.01%

Debt

Sales & Book Value

Annual Sales
$53.90 million
Book Value
$12.86 per share

Miscellaneous

Free Float
36,164,000
Market Cap
$2.59 billion
Optionable
Optionable
Beta
0.41

Key Executives

  • Gene G. KinneyGene G. Kinney
    President, Chief Executive Officer & Director
  • Brandon S. Smith
    Chief Operating Officer
  • Tran B. Nguyen
    Chief Financial & Strategy Officer
  • Wagner M. ZagoWagner M. Zago
    Chief Scientific Officer
  • Hideki Garren
    Chief Medical Officer













PRTA Stock - Frequently Asked Questions

Should I buy or sell Prothena stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PRTA shares.
View PRTA analyst ratings
or view top-rated stocks.

What is Prothena's stock price forecast for 2023?

8 brokerages have issued 1-year price targets for Prothena's shares. Their PRTA share price forecasts range from $55.00 to $120.00. On average, they anticipate the company's stock price to reach $82.50 in the next twelve months. This suggests a possible upside of 67.3% from the stock's current price.
View analysts price targets for PRTA
or view top-rated stocks among Wall Street analysts.

How have PRTA shares performed in 2023?

Prothena's stock was trading at $60.25 on January 1st, 2023. Since then, PRTA shares have decreased by 18.2% and is now trading at $49.30.
View the best growth stocks for 2023 here
.

When is Prothena's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our PRTA earnings forecast
.

How were Prothena's earnings last quarter?

Prothena Co. plc (NASDAQ:PRTA) announced its quarterly earnings results on Thursday, February, 23rd. The biotechnology company reported $0.12 earnings per share for the quarter, topping analysts' consensus estimates of ($0.64) by $0.76. The biotechnology company had revenue of $49.90 million for the quarter, compared to analysts' expectations of $29.14 million. Prothena had a negative net margin of 216.95% and a negative trailing twelve-month return on equity of 24.98%. The company's revenue was up 4058.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.71) earnings per share.

What other stocks do shareholders of Prothena own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prothena investors own include Cara Therapeutics (CARA), Actinium Pharmaceuticals (ATNM), ArcelorMittal (MT), Merck & Co., Inc. (MRK), Energous (WATT), BioLineRx (BLRX), Gilead Sciences (GILD), Exelixis (EXEL) and ACADIA Pharmaceuticals (ACAD).

What is Prothena's stock symbol?

Prothena trades on the NASDAQ under the ticker symbol "PRTA."

Who are Prothena's major shareholders?

Prothena's stock is owned by many different institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (6.63%), Avidity Partners Management LP (6.10%), First Light Asset Management LLC (3.17%), Dimensional Fund Advisors LP (2.73%), T. Rowe Price Investment Management Inc. (1.92%) and Geode Capital Management LLC (1.48%). Insiders that own company stock include Carol D Karp, Christopher S Henney, Christopher S Henney, Dennis J Selkoe, Dennis J Selkoe, Ecor1 Capital, Llc, Gene G Kinney, Hideki Garren, Karin L Walker, Karin L Walker, Lars Ekman, Michael J Malecek, Michael J Malecek, Richard T Collier, Shane Cooke, Tran Nguyen and Wagner M Zago.
View institutional ownership trends
.

How do I buy shares of Prothena?

Shares of PRTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Prothena's stock price today?

One share of PRTA stock can currently be purchased for approximately $49.30.

How much money does Prothena make?

Prothena (NASDAQ:PRTA) has a market capitalization of $2.59 billion and generates $53.90 million in revenue each year. The biotechnology company earns $-116,950,000.00 in net income (profit) each year or ($2.51) on an earnings per share basis.

How can I contact Prothena?

Prothena's mailing address is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN 2 L2, D02 T804. The official website for the company is www.prothena.com. The biotechnology company can be reached via phone at (531) 236-2500, via email at ellen.rose@prothena.com, or via fax at 353-1902-3510.

This page (NASDAQ:PRTA) was last updated on 3/29/2023 by MarketBeat.com Staff